Ruth Rosentreter
Family · Fairbanks, AKNPI 1770146698
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 34.1% of the total.
Across 41 payments — averaging $31.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$447
- AstraZeneca$184
- Biohaven Pharmaceutical Holding Company Ltd.$156
- Novo Nordisk$155
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$100
- Exact Sciences$50
- plus $219 from 10 others
What the payments were for
- Food & beverage$1,312100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $447 |
| AstraZeneca | 5 | $184 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $156 |
| Novo Nordisk | 3 | $155 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $100 |
| Exact Sciences | 3 | $50 |
| Pfizer | 2 | $39 |
| Janssen Scientific Affairs, LLC | 1 | $29 |
| Lundbeck LLC | 1 | $26 |
| Novartis | 1 | $21 |
| Baxter Healthcare | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Alkermes, Inc. | 1 | $17 |
| Indivior Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$233
- Saxenda$120
- FARXIGA$120
- NURTEC ODT$115
How this compares
$1,312 in reported general payments places this provider in the 80th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $16,376 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $1,384 |
| Levothyroxine Sodium | 38 | $515 |
| Atorvastatin Calcium | 43 | $460 |
| Lisinopril | 35 | $392 |
| Pantoprazole Sodium | 18 | $368 |
| Celecoxib | 12 | $345 |
| Gabapentin | 13 | $222 |
| Omeprazole | 23 | $217 |
| Fluticasone Propionate | 11 | $176 |
| Oxybutynin Chloride | 11 | $172 |
| Potassium Chloride | 19 | $160 |
| Rosuvastatin Calcium | 16 | $155 |
| Losartan Potassium | 16 | $132 |
| Alendronate Sodium | 13 | $119 |
Paid to pharmacies, not to this prescriber.
Other family in Fairbanks
- Kristy BloodFairbanks$7K
- Casey BloodFairbanks$7K
- Teal VingerFairbanks$5K
- Brianna GrahamFairbanks$4K
- Joan DigeorgeFairbanks$3K
- Robert RosentreterFairbanks$2K
- Karolina PriebeFairbanks$2K
- Erica HeagyAnchorage$249K
- Trisha KernodleAnchorage$60K
- Whitney CarlsonSoldotna$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.